- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03035929
Diagnosing Natriuretic Peptide Deficiency
Diagnosing Natriuretic Peptide Deficiency: A Pilot Study
In this pilot study, the investigators will determine the response of the natriuretic peptide (NP) hormone system after a dose of intravenous dexamethasone (a steroid medication). The goal of the proposed project is to generate preliminary data that will be used to develop power calculations, inform cutoff ranges, and inform the timing of the NP response for larger subsequent studies.
Aim: To determine the range of distribution and time course of natriuretic peptide (NP) responses to a single dose of dexamethasone IV 4 mg in healthy lean individuals.
Hypothesis: Determination of the NP responses (the range and time course of changes in NP levels) to dexamethasone in 10 healthy individuals will inform the time course and frequency of blood sampling in a definitive prospective study, as well as enable investigators to perform a sample size calculation for a definitive prospective study.
Studieoversigt
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Vanderbilt University Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria:
- Men and women ages 18-50 years
- BMI 18.5 to <25 kg/m^2
Exclusion Criteria:
- Significant use of systemically-absorbed glucocorticoids currently or for an extended period of time during the prior 6 months
- Current use of antihypertensive medications
- Current use of metformin, or any antidiabetic medications (which could affect glucose and insulin levels)
- Current use of medications known to affect dexamethasone metabolism, including phenytoin, rifampin, carbamazepine, troglitazone, and barbiturates
- Active, clinically significant infection at time of visit
- History of adrenal insufficiency or Cushing's syndrome
- Prior or current cardiovascular disease, renal disease, or liver disease
- Diabetes mellitus, pre-diabetes, impaired fasting glucose, or impaired glucose tolerance
- Atrial fibrillation
- Bleeding disorder or anemia
- Elevated Liver Functions Tests > 2 times upper limit of normal
- Estimated glomerular filtration rate < 60 ml/min
- HbA1c > 5.7
- Abnormal sodium or potassium level
- Positive pregnancy test, women of child-bearing age not practicing birth control, women who are breastfeeding
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Healthy
10 Healthy subjects will undergo study procedures at four study visits. All subjects will undergo the same procedures and interventions. |
A single dose of dexamethasone IV 4 mg will be administered.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Changes in NT-proANP From Baseline to 8 Hours
Tidsramme: baseline and 8 hours
|
Change in natriuretic peptide levels after drug administration
|
baseline and 8 hours
|
Changes in NT-proBNP From Baseline to 8 Hours
Tidsramme: Baseline and 8 hours
|
Change in natriuretic peptide levels after drug administration
|
Baseline and 8 hours
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Changes in NT-proANP
Tidsramme: baseline, 24 hours, 48 hours and 72 hours
|
Change in natriuretic peptide levels after drug administration from baseline to 24 hours, 48 hours, and 72 hours
|
baseline, 24 hours, 48 hours and 72 hours
|
Changes in NT-proBNP
Tidsramme: at baseline, 24 hours, 48 hours and 72 hours
|
Change in natriuretic peptide levels after drug administration from baseline to 24 hours, 48 hours, and 72 hours
|
at baseline, 24 hours, 48 hours and 72 hours
|
BNP (B-type Natriuretic Peptide)
Tidsramme: 0-8 hrs, 24 hrs, 48 hrs, 72 hrs after drug administration
|
Natriuretic peptide levels after drug administration
|
0-8 hrs, 24 hrs, 48 hrs, 72 hrs after drug administration
|
ANP (Atrial Natriuretic Peptide)
Tidsramme: 0-8 hrs, 24 hrs, 48 hrs, 72 hrs after drug administration
|
Natriuretic peptide levels after drug administration
|
0-8 hrs, 24 hrs, 48 hrs, 72 hrs after drug administration
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Katherine N Bachmann, MD, Vanderbilt Endocrinology
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Autonome agenter
- Agenter fra det perifere nervesystem
- Enzymhæmmere
- Anti-inflammatoriske midler
- Antineoplastiske midler
- Antiemetika
- Gastrointestinale midler
- Glukokortikoider
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Antineoplastiske midler, hormonelle
- Proteasehæmmere
- Dexamethason
- Dexamethasonacetat
- BB 1101
Andre undersøgelses-id-numre
- 161482
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Dexamethasone
-
Universitätsklinikum Hamburg-EppendorfGemeinsamer Bundesausschuss (G-BA); Staburo GmbHRekruttering
-
Vanderbilt University Medical CenterAfsluttetAstma | KrydsForenede Stater
-
Shanghai Jiao Tong University Affiliated Sixth...AfsluttetAnalgesi | Tid | Brachial Plexus Blok | Skulderkirurgi | Dexamethason | Intravenøs medicinbrugKina
-
Centre hospitalier de l'Université de Montréal...AfsluttetForebyggelse af overfølsomhedsreaktioner over for paclitaxelCanada
-
Cairo UniversityUkendt
-
Dr. Stephen ChoiThe Physicians' Services Incorporated FoundationAfsluttetSkulderkirurgi | NerveblokCanada
-
Ottawa Hospital Research InstituteAfsluttetSmertesyndrom | Brystkræft i tidligt stadieCanada
-
University of BelgradeAfsluttet
-
Poznan University of Medical SciencesRekrutteringHåndledsskader | Håndskader | Håndskader og lidelser | Håndsyge | HåndledssygdomPolen
-
Centre Hospitalier Universitaire VaudoisAfsluttetPostoperativ smerteBelgien